Shamburg News · 8-K filed Nov 13, 2026, 4:51 PM EST
Cerenome Reports Third Quarter 2026 Net Loss of $8.7 Million, or $1.14 Per Share
CNSY · CERENOME, INC.
- Earnings
- Leadership change
- Materiality: high
Cerenome, Inc. reported financial results for the third quarter ended September 30, 2026, with total revenue of $0.7 million, all from net diagnostic revenue. Operating loss was $7.5 million and net loss was $8.7 million, or $1.14 per share, compared with a net loss of $4.4 million, or $1.03 per share, a year earlier. Cash, cash equivalents and investments totaled $4.9 million as of September 30, 2026. The filing also reported an Aetna in-network agreement for CNSide, the first-quarter CNSide diagnostic revenue, and progress in the REYOBIQ clinical program.
Source: SEC EDGAR, Form 8-K, Items 2.02, 9.01, accession 0001193125-26-460887.
Written from the filing by Shamburg Markets. Figures are as reported by the company.